Author(s) :
Petru Vladimir Filip1 , Marius Farcaș2
1Department of Infectious Diseases, Clinical Hospital for Infectious Diseases, Cluj-Napoca, Romania
2 Department of Clinical Hematology, Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
Corresponding author: Petru Vladimir Filip, Email: vladimirpfilip@gmail.com
Publication History: Received - , Revised - , Accepted - , Published Online - 1 April 2023.
Copyright: © The author(s). Published by Casa Cărții de Știință.
User License: Creative Commons Attribution – NonCommercial (CC BY-NC)
PDF
Share
Abstract
In the last decade, lung cancer patients have benefited from novel and efficient therapies such as immunotherapy. However, currently, there is no standardized method for predicting the success of immunotherapy. We review the potential immune markers such as the tumor mutational burden (TMB), the presence of intratumor infiltrating lymphocytes (TIL), the neutrophils/ lymphocytes ratio (NLR) and microsatellite instability (MSI), providing a summary of their reported utility, prognostic and predictive value.
| Ref | Patient
cohort |
Therapy | ORR | PFS | OS | CI 95% |
| (8) | 81 | Atezolizumab monotherapy | 13.6% | – | – | – |
| (10) | 256 | Pembrolizumab Pt-doublet based CT | – | – | 12.5 mo | 9.8-16.4 mo |
| (11) | 22 | Sintilimab (anti PD-1) + Anlotinib (anti-VEGFR) | 72.7%
|
15 mo | – | 49.8-89.3% |
| (12) | 173 | Pembrolizumab
Quavonlimab (anti-CTLA4) |
40% | – | – | 24.9-56.7% |
| (13) | 41 | Sintilimab (anti PD-1) + CT | 68.4% | – | – | 43.4-87.4% |
| (14) | 55 | Nivolumab + Neoantigenic Vaccine | 39% | 8.5 mo | 83% | 17-64% |
| (15) | 572 | Atezolizumab vs CT | –
|
8,1 mo | 20.2 mo | – |
| (16) | 176 | Unspecified Anti PD-1/PDL-1 | – | – | 51% (OS rate) | – |
| (17)
|
1118 | Durvalumab + Tremelimumab CT | – | 3.9 mo | 16.3 mo | 12.2-20.8 mo |
| (28) | 126 | Sotorasib (anti KRAS)+ Unspecified anti PD1/PD-1 | 37.1%
|
6.8 mo | 12.5 mo | 28.6-46.2% |